Clinical imaging and COVID-19: Czernin and colleagues provide first-hand reports of global clinical experiences with nuclear medicine practice during the pandemic as well as strategies and precautions implemented. Page 626

COVID-19 and PE: Zuckier and colleagues look at risks and alternatives to ventilation/perfusion scintigraphy for pulmonary embolism assessment during the current virus pandemic. Page 630

Incidental pneumonia and COVID-19: Albano and colleagues report on local experience with identification of COVID-19 in incidental pneumonia findings from nuclear imaging procedures performed for standard oncologic indications. Page 632

New JNM features: Czernin previews “The Standard of Care,” a series of review articles focusing on evolving clinical knowledge and training in nuclear and molecular medicine, as well as a series on challenging case studies. Page 637

Discussions with leaders: Ken Hermann talks with Ignasi Carrión, a former president of the European Association of Nuclear Medicine and immediate past-editor-in-chief of the European Journal of Nuclear Medicine and Molecular Imaging. Page 638

Novel tracers in immunotherapy: Niemeijer and colleagues discuss opportunities and challenges for PET as an imaging biomarker in the field of immune checkpoint inhibitor therapy, including applications in response prediction, treatment evaluation, and new drug development. Page 641

Genotype and PPGL imaging: Tabei and Pacak offer perspective on the ways in which genotype can be considered a critical determinant of imaging phenotype in phaeochromocytoma and paraganglioma and at the current role and potential for genetic screening. Page 643

Analyzing paraganglioma imaging: Tabei and colleagues identify levels of data analysis in imaging, including foci on lesion detection, imaging-derived biomarkers, and genotypic approaches, using paraganglioma as an example. Page 646

Early PET after anti-PD1 in HL: Chen and colleagues investigate whether early response evaluation by 18F-FDG PET/CT is predictive of overall survival in patients with relapsed or refractory Hodgkin leukemia treated with anti–programmed cell death 1 monoclonal antibodies. Page 649

Fluorescence imaging of rectal margins: de Jongh and colleagues explore the feasibility of optical molecular imaging as a tool for evaluating circumferential resection margins directly after surgical resection to enhance perioperative decision making in locally advanced rectal cancer. Page 655

Assessing pediatric CSF flow: Kramer and colleagues define the incidence of normal, delayed, asymmetric, and obstructed cerebrospinal fluid flow in a large pediatric population with central nervous system tumors before administration of intraventricular radioimmunotherapy. Page 662

Breast cancer: 18F-ISO-1 uptake and Ki-67: McDonald and colleagues report the results of the first dedicated clinical trial of 18F-ISO-1 in primary breast cancer, designed to determine whether 18F-ISO-1 PET can provide in vivo measures of tumor proliferative status. Page 665

22Ra response on automated bone scan index: Anand and colleagues evaluate an automated bone scan index as a quantitative assessment of bone scans for radiographic response to 22Ra treatment in patients with metastatic castration-resistant prostate cancer. Page 671

Building on ProPSMA: Hofman looks briefly at the results of the Australian collaborative ProPSMA study, published recently in The Lancet, and calls for additional unbiased and detailed studies of prostate-specific membrane antigen imaging. Page 676

PSMA PET progression criteria: Fanti and colleagues define prostate cancer progression by criteria for prostate-specific membrane antigen PET, based on the principles applied by the Prostate Cancer Clinical Trials Working Group 2 but with the added value of PET inclusion. Page 678

PSMA-TAT and mutated DNA repair genes: Kratochwil and colleagues use targeted next-generation sequencing to characterize nonresponding lesions in prostate-specific membrane antigen–targeting α-radiation therapy. Page 683

Response prediction after PSMA therapy: Rathke and colleagues assess whether chromogranin A can serve as a response predictor for 177Lu-prostate-specific membrane antigen 617 prostate cancer therapy in comparison with established tumor markers. Page 689

18F-rhPSMA-7 PET and BCR: Eiber and colleagues describe the efficacy of an 18F-labeled radiohybrid prostate-specific membrane antigen, rhPSMA-7, as a novel theranostic PSMA-targeting PET agent for biochemical recurrence of prostate cancer. Page 696

18F-rhPSMA-7 biodistribution: Oh and colleagues detail the biodistribution and image quality of 18F-rhPSMA-7, one of a new class of theranostic prostate-specific membrane antigen–targeting agents, to determine optimal PET/CT imaging time points for patients with prostate cancer. Page 702

18F-rhPSMA-7 PET and primary N-staging: Kroenne and colleagues report on a retrospective analysis using PET/CT and PET/MRI to investigate the efficacy of 18F-rhPSMA-7 PET for primary N-staging of patients with prostate cancer, with comparisons to morphologic imaging and histopathologic validation. Page 710

Module versus kit synthesis for PSMA: Calderoni and colleagues assess the image quality of 68Ga-prostate-specific membrane antigen-11 PET/CT in prostate cancer patients after injection of tracers obtained using synthesis modules or sterile cold kits. Page 716

PSMA therapy and SIRT in PCa: Seifert and colleagues describe the efficacy of 177Lu-prostate-specific membrane antigen-617 and selective internal radiation therapy for liver metastases in castration-resistant prostate cancer. Page 723

Comparing PSMA PET tracers: Dietlein and colleagues benchmark the performance of 18F-prostate-specific membrane antigen 1007 PET/CT in patients with relapsed prostate cancer and previously equivocal, negative, or oligometastatic findings with 68Ga-PSMA-11, 18F-rhPSMA-7, 18F-DCEPyL, or 18F-JK-PSMA-7. Page 729

Radiohybrid ligands: Wurzer and colleagues describe development of inhibitors of the prostate-specific membrane antigen labeled by isotopic exchange and evaluate 6 radiohybrid PSMA ligands in comparison with 18F-rhPSMA-1007. Page 735

Imaging γH2AX after 177Lu-DOTATATE: O’Neill and colleagues visualize and quantify the extent of DNA damage response in mice after 177Lu-DOTATATE therapy using SPECT imaging with 111In-anti-γH2AX-TAT. Page 743

CXCR4-directed PET/CT in atherosclerosis: Kircher and colleagues investigate the performance of 68Ga-plexitaxofar PET/CT for chemokine-directed imaging of atherosclerosis and compare results with those from 18F-FDG PET/CT. Page 751

Imaging brain leukocytes: Chen and colleagues report on the ability of 18F-FAC PET to visualize brain-infiltrating leukocytes in a mouse multiple sclerosis model and to monitor the response of these cells to an immunomodulatory drug. Page 757

Activity optimization with Vision PET/CT: van Sluis and colleagues explore the effects of reduced scan duration in oncologic 18F-FDG PET imaging on quantitative and subjective imaging parameters and its influence on clinical image interpretation. Page 764